https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
8 [range 29-140] months in the aHSCT group compared to 27.6 [range 11-52] months in the alemtuzumab-treated group. We observed significantly more patients maintaining NEDA in the aHSCT group (p=0.048) compared to the alemtuzumab-treated patients. Furthermore, 37% of the aHSCT patients showed an improvement of EDSS compared to none in the alemtuzumab-treated group (p=0.033). It is of note that cognitive function was significantly improved in the aHSCT-treated patients. aHSCT suppresses inflammatory activity more effectively t
Like
Comment
Share
